|
Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial. |
|
|
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Genmab; Roche/Genentech |
Research Funding - Genmab; Roche |
|
|
Employment - Helsinki University Hospital |
Leadership - Celgene; Finnish Cancer Organizations; Gilead Sciences; Incyte; MSD; Novartis; Roche |
Honoraria - Gilead Sciences; Incyte; Novartis |
Consulting or Advisory Role - Celgene; CHO Pharma Usa Inc; Finnish Cancer Organizations; Gilead Sciences; Incyte; MSD; Novartis; Orion; Roche |
Speakers' Bureau - Gilead Sciences; Incyte; Novartis |
Research Funding - Bayer; Celgene; Genmab; Nordic Nanovector; Novartis; Roche; Takeda |
|
|
Consulting or Advisory Role - Roche |
Research Funding - Gilead Sciences; Roche |
|
|
Consulting or Advisory Role - Genmab |
Research Funding - Roche; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Gilead Sciences; Incyte; Novartis; Roche; Takeda |
Research Funding - Incyte |
Other Relationship - Genmab; Nordic Nanovector |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
Employment - Genmab; Novartis |
Stock and Other Ownership Interests - Genmab; Novartis |
Patents, Royalties, Other Intellectual Property - Patents pending related to Genmab development of epcoritamab |
Travel, Accommodations, Expenses - Genmab; Novartis |
|
|
Consulting or Advisory Role - Debiopharm Group; Gilead Sciences; Janssen-Cilag; MorphoSys; Roche; Takeda |
Research Funding - Dr. Reddy's (Inst); Genmab (Inst); Gilead Sciences (Inst); Janssen-Cilag (Inst); MorphoSys (Inst); Pharmacyclics (Inst); Roche (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Gilead Sciences; Roche; Takeda |